Explore our news page for thought leadership articles, technical expertise and the latest developments in the world of innovation funding.
Filter
The Grants team at Myriad Associates are proud to announce that they have secured over €30m from the Disruptive Technologies Innovation Fund (DTIF).
Onkimmune was founded in 2015 with the goal of developing novel anti-cancer therapies using Natural Killer (NK) cells.
Myriad Associates is proud to announce that 4 of our clients who applied for the Disruptive Technologies Innovation Fund were all approved on Monday 10th December.